20161212-MBX_logo_lrg.jpg
Microbix Announces Board Changes
September 15, 2020 07:00 ET | Microbix Biosystems Inc.
William J. Gastle retiring, Martin Marino nominated to become Independent Chairman MISSISSAUGA, Ontario, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF,...
logo.png
Soricimed Publishes New Research Validating TRPV6 as a Therapeutic Target for Ovarian Cancer
October 31, 2018 15:00 ET | Soricimed Biopharma Inc.
MONCTON, New Brunswick, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing targeted cancer therapeutics, is...
logo.png
Soricimed Announces Changes to its Board of Directors
September 04, 2018 07:00 ET | Soricimed Biopharma Inc.
MONCTON, New Brunswick, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing targeted cancer therapeutics, is...
Soricimed annonce la nomination du Dr Marc Rubin et de M. Vaughn Embro-Pantalony à son conseil d’administration
March 19, 2018 14:38 ET | Soricimed Biopharma Inc.
MONCTON, Nouveau-Brunswick, 19 mars 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. (« Soricimed »), compagnie pharmaceutique au stade clinique spécialisée dans la recherche et la mise au point de...
Soricimed Announces the Appointment of Dr. Marc Rubin and Mr. Vaughn Embro-Pantalony to Board of Directors
March 19, 2018 14:30 ET | Soricimed Biopharma Inc.
MONCTON, New Brunswick, March 19, 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing targeted cancer therapeutics, is...
Soricimed Publishes the Results of Phase I Study of SOR-C13 in Patients with Advanced Solid Tumors
February 21, 2017 07:30 ET | Soricimed Biopharma Inc.
TORONTO, ONTARIO--(Marketwired - Feb. 21, 2017) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer...
Soricimed publie les résultats d'une étude de phase I du SOR-C13 chez les patients atteints de tumeurs solides avancées
February 21, 2017 07:30 ET | Soricimed Biopharma Inc.
TORONTO, ONTARIO--(Marketwired - 21 fév. 2017) - Soricimed Biopharma Inc. (« Soricimed »), une compagnie pharmaceutique au stade clinique spécialisée dans la...
Soricimed's SOR-C13 Granted Orphan Drug Designation for Pancreatic Cancer by the U.S. FDA
September 27, 2016 07:30 ET | Soricimed Biopharma Inc.
TORONTO, ONTARIO--(Marketwired - Sept. 27, 2016) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer...
La FDA accorde la désignation de médicament orphelin à SOR-C13 pour le cancer du pancréas
September 27, 2016 07:30 ET | Soricimed Biopharma Inc.
TORONTO, ONTARIO--(Marketwired - 27 sept. 2016) - Soricimed Biopharma Inc. (« Soricimed »), compagnie pharmaceutique spécialisée dans la recherche et la mise au point...
Soricimed Announces Clinical Advisory Board
July 06, 2016 10:30 ET | Soricimed Biopharma Inc.
TORONTO, CANADA--(Marketwired - July 6, 2016) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company developing first-in-class peptide-based cancer therapeutics,...